Form 4: Neurocrine Biosciences Executive Ingrid Delaet Reports Stock Transactions

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• On July 16, 2024, Delaet exercised non-qualified stock options to acquire 1,957 shares of common stock at a price of $103.52 per share.
• Concurrently, Delaet sold 2,857 shares of common stock at weighted average prices ranging from $150.00 to $150.21 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2023.
• Following these transactions, Delaet directly owns 6,607 shares of Neurocrine Biosciences common stock and 25,092 non-qualified stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing trading plan, without indicating any positive or negative outlook.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates any significant concerns.

Key Dates